Press Releases Immatics N.V.

Equities

IMTX

NL0015285941

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
11.03 ^USD	-2.22%		-5.73%	+4.75%

May. 15	Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating	MT
May. 14	Immatics' Q1 Loss Narrows. Revenue Rises	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immatics: Q1 Earnings Snapshot	May. 14	AQ
Immatics N : Corporate Presentation May 2024	May. 14	PU
Immatics Announces First Quarter 2024 Financial Results and Business Update	May. 14	GL
Immatics N : Corporate Presentation March 2024	Mar. 21	PU
Immatics Announces Full Year 2023 Financial Results and Corporate Update	Mar. 21	GL
Immatics Announces Pricing of $175 Million Public Offering	Jan. 17	GL
Immatics Announces Pricing of $175 Million Public Offering	Jan. 17	AQ
Immatics Announces Proposed Public Offering	Jan. 17	GL
Immatics Announces Proposed Public Offering	Jan. 17	AQ
Immatics: Q3 Earnings Snapshot	Nov. 14	AQ
Immatics Announces Third Quarter 2023 Financial Results and Business Update	Nov. 14	GL
Immatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial	Nov. 09	AQ
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial	Nov. 08	GL
Immatics N : ACTengine® IMA203 Clinical Data Update at Society for Melanoma Research Congress, November 2023	Nov. 07	PU
Immatics Receives FDA Regenerative Medicine Advanced Therapy Designation for ACTengine IMA203 TCR-T Monotherapy	23-10-25	AQ
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy	23-10-24	GL
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy	23-10-24	AQ
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors	23-09-13	AQ
MODERNA AND IMMATICS ANNOUNCE STRATEGIC MULTI-PLATFORM COLLABORATION TO DEVELOP INNOVATIVE ONCOLOGY THERAPEUTICS	23-09-12	AQ
Immatics N : Corporate Presentation, September 2023	23-09-11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immatics N.V.

Equities

IMTX

NL0015285941

Press Releases

Filters